Merck & Co., Inc.: financial analysis
Ratios worked out from 10 fiscal years of Merck & Co., Inc.'s statements, compared with 102 companies in Pharmaceutical.
Merck & Co., Inc. scorecard#
Passes 16 of the 24 checks that could be worked out: strongest in profitability (3 of 3), weakest in valuation (0 of 6). Fiscal year 2025; market cap of Oct 19, 2026.
Valuation0 of 6
- ✗P/E below its peers' median146.7×P/E 146.7× against Pharmaceutical's median of 39.4×.
- ✗Price to book below its peers' median6.8×Price to book 6.8× against Pharmaceutical's median of 3.2×.
- ✗Price to sales below its peers' median5.3×Price to sales 5.3× against Pharmaceutical's median of 3.5×.
- ✗Free cash flow yield above 5%3.4%Free cash flow is 3.4% of the market value.
- ✗Earnings yield above the 10-year Treasury yield0.7%Earnings yield 0.7% against the 10-year Treasury's 4.92% on 2026-11-20.
- ✗The price assumes slower growth than the last three years'12.9%The price assumes 12.9% a year for ten years; revenue grew 3.1% a year over the last three.
Growth5 of 6
- ✓Revenue grew in the newest year1.3%Revenue up 1.3% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years3.1%3.1% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median3.1%3.1% a year against Pharmaceutical's median of 2.5% (65 companies).
- ✓Earnings per share grew in the newest year7.28 vs 6.74Diluted EPS 7.28 in fiscal 2025 against 6.74 the year before (report's currency).
- ✓Net income higher than five years earlier$18.3 B$18.3 B in fiscal 2025 against $7.1 B in 2020.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2025.
Profitability3 of 3
- ✓Profitable in the newest year$18.3 BNet income $18.3 B in fiscal 2025.
- ✓Profitable in each of the last five years5 of 5Profitable in 5 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✓Return on equity above 15%36.9%36.9% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health3 of 3
- ✓Short-term assets cover short-term liabilities1.5×Current ratio 1.54 at the end of fiscal 2025.
- ✓Debt below equity0.9×Debt to equity 0.89 at the end of fiscal 2025.
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns5 of 6
- ✓Pays a dividendYesPaid dividends in fiscal 2025.
- ✓Dividend per share raised five years in a row5 of 5Dividend per share raised in 5 of the five years to fiscal 2025.
- ✓Dividends under 75% of net income44.8%Dividends were 44.8% of net income in fiscal 2025.
- ✓Share count up no more than 2% in a year-1.3%Diluted shares down 1.3% in fiscal 2025.
- ✓Dividends and buybacks above 3% of the market value3.7%Dividends and buybacks were 3.7% of the market value.
- ✗Free cash flow covers dividends and buybacks$12.4 BFree cash flow $12.4 B against $13.3 B paid out in fiscal 2025.
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2025 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Strengths
- Revenue has grown 6 years in a row.
- Free cash flow has been positive 17 years in a row.
- The dividend per share has been raised 15 years in a row.
Worth a look
- Total debt rose 36% in the year, to $46.8 billion.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profityes
- Operations brought in cashyes
- Return on assets roseno
- Cash from operations exceeds profitno
- Long-term debt fell against assetsno
- Current ratio roseyes
- No new shares issuedyes
- Gross margin roseno
- Asset turnover roseno
Where the return on equity comes from
The DuPont split: margin, times how hard the assets work, times how much of them is financed by others.
Profitability#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 74.8% | 76.3% | 73.2% | 70.6% | 72.0% | 53.3% | 85% | |
| Net margin | 28.1% | 26.7% | 0.6% | 24.5% | 26.8% | -1.5% | 97% | |
| Return on equity | 36.9% | 40.8% | 0.9% | 34.5% | 41.1% | -0.9% | 90% | |
| Return on assets | 14.4% | 15.3% | 0.3% | 13.5% | 13.2% | -1.3% | 90% |
Growth#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | 1.3% | 6.7% | 1.4% | 21.7% | 17.3% | 7.3% | 30% | |
| Revenue growth, 3 years a year | 3.1% | 9.6% | 13.1% | 14.9% | 4.8% | 2.5% | 53% | |
| Revenue growth, 5 years a year | 9.4% | 10.4% | 7.3% | 8.1% | 4.1% | 6.0% | 67% | |
| Net income growth | 6.6% | — | — | 11.3% | 84.7% | 14.3% | 40% | |
| Earnings per share growth | 8.0% | — | — | 11.1% | 84.9% | 12.4% | 43% |
Financial strength#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Debt to equity | 0.89× | 0.74× | 0.90× | 0.63× | 0.80× | 0.66× | 37% | |
| Net debt | $32.2 B | $21.2 B | $26.8 B | $16.1 B | $22.6 B | $188 M | 11% | |
| Current ratio | 1.54× | 1.36× | 1.25× | 1.47× | 1.27× | 1.98× | 41% | |
| Equity share of assets | 38.4% | 39.6% | 35.2% | 42.1% | 36.1% | 47.3% | 39% |
Cash#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $12.4 B | $18.1 B | $9.1 B | $14.7 B | $8.7 B | $8 M | 96% | |
| Free cash flow margin | 19.0% | 28.2% | 15.2% | 24.8% | 17.8% | 6.0% | 82% | |
| Cash conversion | 90.2% | 125.4% | — | 131.5% | 100.6% | 136.7% | 23% | |
| Capital spending share of revenue | 6.3% | 5.3% | 6.4% | 7.4% | 9.1% | 2.6% | — |
Efficiency#
| Fiscal year | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 0.51× | 0.57× | 0.56× | 0.55× | 0.49× | 0.55× | 43% |
How each figure is worked out#
- Gross margin
- Gross profit as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Revenue growth
- Revenue against the year before.
- Revenue growth, 3 years a year
- The yearly rate that takes revenue of three years earlier to this year's.
- Revenue growth, 5 years a year
- The yearly rate that takes revenue of five years earlier to this year's.
- Net income growth
- Net income against the year before. Only when both years were profitable.
- Earnings per share growth
- Diluted earnings per share against the year before. Only when both were positive.
- Debt to equity
- Total debt divided by shareholders' equity. Not given when equity is negative.
- Net debt
- Total debt less cash. Negative means more cash than debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Cash conversion
- Cash from operations as a share of net income. Only when the year was profitable.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Dividend yield
- Dividends paid in the fiscal year as a share of today's market value.
- Buyback yield
- Shares bought back in the fiscal year as a share of today's market value.
- Shareholder yield
- Dividends plus buybacks as a share of today's market value.
- Dividend payout
- Dividends paid as a share of net income. Only when the year was profitable.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).